IGF2BP2: A Potential Drug Target and Biomarker for Insulin-Like Growth Factor-Responsive Cancer

Target Name: IGF2BP2

NCBI ID: G10644

IGF2BP2

IGF2BP2: A Potential Drug Target and Biomarker for Insulin-Like Growth Factor-Responsive Cancer

Insulin-like growth factor (IGF) signaling is a critical pathway involved in cell growth, development, and survival. The IGF2BP2 gene, which encodes the protein IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2), has been identified as a potential drug target and biomarker for insulin-like growth factor-responsive cancer. In this article, we will discuss the biology of IGF2BP2, its role in cancer progression, and the potential for IGF2BP2 as a drug target and biomarker.

Biography of IGF2BP2

IGF2BP2 is a 22kDa protein that belongs to the insulin-like growth factor (IGF) signaling pathway. IGF2BP2 is highly expressed in various tissues, including adipose tissue, bone marrow, and brain, and its expression is typically highest in tissues that require high levels of IGF signaling. IGF2BP2 has been shown to play a role in cell signaling, including cell proliferation, differentiation, and survival.

IGF2BP2 has also been shown to contribute to cancer progression. For example, IGF2BP2 has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and prostate cancers. In addition, IGF2BP2 has been shown to promote the development of resistant cancer cells, which can reduce the effectiveness of traditional cancer treatments.

Potential Drug Target

The IGF2BP2 gene has been identified as a potential drug target for cancer treatment. By inhibiting IGF2BP2 signaling, cancer cells may be forced to rely on alternative signaling pathways for cell growth and survival. This approach has been shown to be effective in targeting IGF2BP2-responsive cancer cells, including those that are resistant to traditional cancer treatments.

One of the compounds that has been shown to be effective in inhibiting IGF2BP2 signaling is pipefit-1 (P1). P1 is a small molecule that inhibits the activity of the IGF2BP2 protein. P1 has been shown to be effective in treating various types of cancer, including breast, ovarian, and prostate cancers.

Biomarker

IGF2BP2 has also been identified as a potential biomarker for cancer diagnosis and treatment. For example, IGF2BP2 has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancers. In addition, IGF2BP2 has been shown to be associated with cancer outcomes, such as tumor growth and the development of invasive cancer.

Conclusion

IGF2BP2 is a protein that has been shown to play a critical role in cell signaling and cancer progression. As a potential drug target and biomarker, IGF2BP2 has the potential to be a valuable tool in the treatment of insulin-like growth factor-responsive cancer. Further research is needed to fully understand the role of IGF2BP2 in cancer biology and to develop effective treatments based on IGF2BP2 inhibition.

Protein Name: Insulin Like Growth Factor 2 MRNA Binding Protein 2

Functions: RNA-binding factor that recruits target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation (By similarity). Preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and increases their stability (PubMed:29476152). Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs (PubMed:9891060). Binding is isoform-specific. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD (PubMed:29476152)

The "IGF2BP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGF2BP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets